WaferGen Gains $10.7M in Stock After Reverse-Merger With Shell Company WaferGen Bio-systems | GenomeWeb
NEW YORK (GenomeWeb News) — WaferGen has completed a reverse merger with WaferGen Bio-systems, a Nevada-based shell company, under which WaferGen backed into WaferGen Bio-systems for an undisclosed sum.  
 
In connection with the deal, the new entity, WaferGen Bio-systems, received a private stock placement worth $10.7 million. The new company’s stock is trading on the Over-the-Counter Bulletin Board under the ticker name WGBS, and was up around 15 percent at $2.30 in afternoon trading today.   
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.